Maxidex (Dexamethasone)

Dexamethasone acts as a glucocorticoid receptor agonist. After binding to intracellular receptors, the complex alters gene transcription, increasing anti‑inflammatory proteins and decreasing pro‑inflammatory cytokines, chemokines and adhesion molecules. This reduces leukocyte migration and vascular permeability in ocular tissues.

The dosing regimen for Maxidex is determined by the prescribing ophthalmologist based on the specific condition, severity and patient response. Typical regimens involve one to several drops per eye daily, with the exact frequency and duration set by the healthcare professional.

Safety data for dexamethasone ophthalmic suspension in pregnancy and lactation are limited. The product is classified as pregnancy category unknown, so it should be used only if the potential benefit justifies any potential risk to the fetus or infant, and under medical supervision.

To order Maxidex, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Maxidex (dexamethasone) is a potent corticosteroid with a high receptor affinity, often providing a stronger anti‑inflammatory effect than lower‑potency agents such as prednisolone eye drops. Its 0.1% concentration allows effective control of inflammation, but clinicians must balance potency with the risk of intra‑ocular pressure rise.

Store Maxidex at room temperature, preferably below 25 °C, in its original container. Protect the suspension from light and moisture, and keep the bottle tightly closed when not in use. Do not freeze the product.

Instill the prescribed number of drops into the affected eye(s) as directed by the ophthalmologist. Typically, the patient tilts the head back, pulls down the lower eyelid, places a drop, and gently closes the eye for a few minutes to allow absorption. Avoid touching the tip of the bottle to the eye or any surface.

The most serious risks associated with Maxidex include a significant rise in intra‑ocular pressure that can lead to glaucoma, cataract formation with long‑term use, and secondary ocular infections or delayed wound healing. Patients should be monitored regularly for these complications.

Maxidex should be avoided in patients with known hypersensitivity to dexamethasone or any formulation component, active untreated ocular infections, or uncontrolled glaucoma. Caution is also advised for individuals with viral eye diseases unless combined with appropriate antiviral therapy.